JPRN-UMIN000033911
Completed
未知
Analysis of allogenic stem cell transplantation for primary immunodeficiency using TRUMP data - Analysis of allo-HCT for PIDs in Japan
ConditionsPrimary immunodeficiency
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Primary immunodeficiency
- Sponsor
- Tokyo Medical and Dental University
- Enrollment
- 800
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The patients whose TRUMP data are insufficient for analysis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CChronic lymphocytic leukemiaMedDRA version: 14.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2007-005487-28-NLHOVON Foundation50
Completed
Phase 2
Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CB-CLL10024324NL-OMON38321HOVO40
Recruiting
Phase 1
Phase I/II clinical trial to assess the safety and biological efficacy of treatment with virus-specific, cytotoxic T-lymphocytes from partially matched third-party unrelated donors, in stem cell transplant patients with viral reactivation unresponsive to standard therapy (R3ACT trial)ACTRN12613000603718Western Sydney Local Health Districit30
Completed
Phase 1
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1HMyelodysplastic DisordersLeukemiaMultiple MyelomaPlasma Cell DyscrasiaLymphoproliferative DisordersNCT00048412Baylor College of Medicine40
Active, not recruiting
Phase 1
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapyMultiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-001005-67-DEniversity Medical Center Hamburg-Eppendorf482